NCT02743013View on ClinicalTrials.gov

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
COPD
Interventions
DRUG

CHF 5993 100/6/12,5 pMDI

DRUG

CHF 5993 100/6/12,5 DPI Test 1

DRUG

CHF 5993 100/6/12,5 DPI Test 2

DRUG

CHF 5993 100/6/12,5 pMDI replicate

DRUG

CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber

Trial Locations (1)

Unknown

SGS CPU Antwerpen, Antwerp

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02743013 - Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers | Biotech Hunter | Biotech Hunter